Home >> Signaling Pathways >> Chromatin/Epigenetics

Chromatin/Epigenetics

Chromatin/Epigenetics

Epigenetics

Epigenetics means above genetics. It determines how much and whether a gene is expressed without changing DNA sequences. Epigenetic regulations include, 1. DNA methylation: the addition of methyl group to DNA, converting cytosine to 5-methylcytosine, mostly at CpG sites; 2. Histone modifications: posttranslational modificationEpigeneticss of histone proteins including acetylation, methylation, ubiquitylation, phosphorylation and sumoylation; 3. miRNAs: non-coding microRNA downregulating gene expression; 4. Prions: infectious proteins viewed as epigenetic agents capable of inducing a phenotype without changing the genome.

Products for  Chromatin/Epigenetics

  1. Cat.No. Product Name Information
  2. GC68474 Pivanex Pivanex  Chemical Structure
  3. GC68439 GNE-064 GNE-064  Chemical Structure
  4. GC68405 Lys-CoA TFA Lys-CoA TFA  Chemical Structure
  5. GC68378 GDC-4379 GDC-4379  Chemical Structure
  6. GC68161 5-AIQ 5-AIQ  Chemical Structure
  7. GC68147 dAURK-4 hydrochloride dAURK-4 hydrochloride  Chemical Structure
  8. GC68035 PARP10/15-IN-1 PARP10/15-IN-1  Chemical Structure
  9. GC68025 UNC1021 UNC1021  Chemical Structure
  10. GC68010 HDAC3-IN-T247 HDAC3-IN-T247  Chemical Structure
  11. GC68006 PARP1-IN-11 PARP1-IN-11  Chemical Structure
  12. GC68000 JAK-IN-23 JAK-IN-23  Chemical Structure
  13. GC67984 Alteminostat Alteminostat  Chemical Structure
  14. GC67962 Simmiparib Simmiparib  Chemical Structure
  15. GC67941 HIF-PHD-IN-1 HIF-PHD-IN-1  Chemical Structure
  16. GC67934 EEDi-5285 EEDi-5285  Chemical Structure
  17. GC67921 Bomedemstat ditosylate Bomedemstat ditosylate  Chemical Structure
  18. GC67912 Amredobresib Amredobresib  Chemical Structure
  19. GC67906 OM-153 OM-153  Chemical Structure
  20. GC67899 Aurora kinase inhibitor-8 Aurora kinase inhibitor-8  Chemical Structure
  21. GC67873 PAD-IN-2 PAD-IN-2  Chemical Structure
  22. GC67867 VVD-118313 VVD-118313  Chemical Structure
  23. GC67863 DDO-2093 dihydrochloride DDO-2093 dihydrochloride  Chemical Structure
  24. GC67778 Sirtuin modulator 3 Sirtuin modulator 3  Chemical Structure
  25. GC67758 MM-401 TFA MM-401 TFA  Chemical Structure
  26. GC67676 Tazemetostat de(methylene morpholine)-O-C3-O-C-COOH Tazemetostat de(methylene morpholine)-O-C3-O-C-COOH  Chemical Structure
  27. GC67674 CRA-026440 hydrochloride CRA-026440 hydrochloride  Chemical Structure
  28. GC52479 Histone H3 (Citrullinated R26) (21-44)-GGK-biotin Peptide (trifluoroacetate salt) A biotinylated peptide fragment of histone H3 Histone H3 (Citrullinated R26) (21-44)-GGK-biotin Peptide (trifluoroacetate salt)  Chemical Structure
  29. GC52371 Vimentin (G146R) (139-159)-biotin Peptide A biotinylated mutant vimentin peptide Vimentin (G146R) (139-159)-biotin Peptide  Chemical Structure
  30. GC52370 Citrullinated Vimentin (R144) (139-159)-biotin Peptide A biotinylated and citrullinated vimentin peptide Citrullinated Vimentin (R144) (139-159)-biotin Peptide  Chemical Structure
  31. GC52368 DL-Sulforaphane Glutathione A metabolite of sulforaphane DL-Sulforaphane Glutathione  Chemical Structure
  32. GC52367 Citrullinated Vimentin (G146R) (R144 + R146) (139-159)-biotin Peptide A biotinylated and citrullinated mutant vimentin peptide Citrullinated Vimentin (G146R) (R144 + R146) (139-159)-biotin Peptide  Chemical Structure
  33. GC52364 Vimentin (139-159)-biotin Peptide A biotinylated vimentin peptide Vimentin (139-159)-biotin Peptide  Chemical Structure
  34. GC52363 Citrullinated Histone H3 (R2 + R8 + R17) (2-22)-biotin Peptide A biotinylated and citrullinated histone H3 peptide Citrullinated Histone H3 (R2 + R8 + R17) (2-22)-biotin Peptide  Chemical Structure
  35. GC52351 Citrullinated α-Enolase (R8 + R14) (1-19)-biotin Peptide A biotinylated and citrullinated α-enolase peptide Citrullinated α-Enolase (R8 + R14) (1-19)-biotin Peptide  Chemical Structure
  36. GC66464 HIF-1α-IN-2 HIF-1α-IN-2 is an effective HIF-1α inhibitor with anticancer potencies (IC50s of 28 nM and 15 nM in MDA-MB-231 and MiaPaCa-2 cells, respectively). HIF-1α-IN-2 suppresses HIF-1α expression by blocking transcription and protein translation. HIF-1α-IN-2  Chemical Structure
  37. GC66441 BRD4/CK2-IN-1 BRD4/CK2-IN-1 is the first highly effective and oral active dual-target inhibitor of BRD4/CK2 (bromodomain-containing protein 4/casein kinase 2), with IC50s of 180 nM and 230 nM for BRD4 and CK2, respectively. BRD4/CK2-IN-1 has strong anticancer activity without obvious toxicities. BRD4/CK2-IN-1 induces apoptosis and autophagy-associated cell death in triple-negative breast cancer (TNBC) BRD4/CK2-IN-1  Chemical Structure
  38. GC66379 AFM-30a hydrochloride AFM-30a hydrochloride is a potent protein arginine deiminase 2 (PAD2) inhibitor and has excellent PAD2-selectivity. AFM-30a hydrochloride binds to PAD2 with an EC50 value of 9.5 μM. AFM-30a hydrochloride also inhibits H3 citrullination with an EC50 value of 0.4 μM. AFM-30a hydrochloride can be used for the research of certain cancers and a variety of autoimmune diseases including rheumatoid arthritis (RA), multiple sclerosis, lupus, and ulcerative colitis. AFM-30a hydrochloride  Chemical Structure
  39. GC66335 PAD2-IN-1 hydrochloride PAD2-IN-1 hydrochloride, a benzimidazole-based derivative, is a potent and selective protein arginine deiminase 2 (PAD2) inhibitor. PAD2-IN-1 hydrochloride shows superior selectivity for PAD2 over PAD4 (95-fold) and PAD3 (79-fold). PAD2-IN-1 hydrochloride  Chemical Structure
  40. GC66329 NDI-034858 NDI-034858 is a TYK2 inhibitor, target TYK2 JH2 domain with binding constant Kd of <200 pM. NDI-034858  Chemical Structure
  41. GC66067 ODM-207 ODM-207 (BET-IN-4) is a potent BET bromodomain protein (BRD4) inhibitor, with an IC50 of ≤ 1 μM. ODM-207  Chemical Structure
  42. GC66055 5-Phenylpentan-2-one 5-Phenylpentan-2-one is a potent histone deacetylases (HDACs) inhibitor. 5-Phenylpentan-2-one can be used for urea cycle disorder research. 5-Phenylpentan-2-one  Chemical Structure
  43. GC66052 HDAC-IN-40 HDAC-IN-40 is a potent alkoxyamide-based HDAC inhibitor with Ki values of 60 nM and 30 nM for HDAC2 and HDAC6, respectively. HDAC-IN-40 had antitumor effects. HDAC-IN-40  Chemical Structure
  44. GC66049 NSC 694621 NSC 694621 is a potent PCAF inhibitor, with an IC50 of 5.71 μM (PCAF/H31-21). NSC 694621 exhibits good activity of inhibiting the proliferation of cancer cells. NSC 694621  Chemical Structure
  45. GC66026 SIRT2-IN-9 SIRT2-IN-9 (compound 12) is a selective inhibitor of SRIT2 with an IC50 value of 1.3 μM. SIRT2-IN-9 inhibits proliferative activity of MCF-7 breast cancer cells. SIRT2-IN-9 can be used for the research of cancer. SIRT2-IN-9  Chemical Structure
  46. GC65980 EZH2-IN-13 EZH2-IN-13 is a potent EZH2 inhibitor, for details please refer to compound 73 in patent WO2017139404. EZH2-IN-13 can be used to study cancers or precancerous lesions associated with EZH2 activity. EZH2-IN-13  Chemical Structure
  47. GC65965 MPT0E028 MPT0E028 is an orally active and selective HDAC inhibitor with IC50s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2 and HDAC6, respectively. MPT0E028 reduces the viability of B-cell lymphomas by inducing apoptosis and possesses potent direct Akt targeting ability and reduces Akt phosphorylation in B-cell lymphoma. MPT0E028 has good anticancer activity. MPT0E028  Chemical Structure
  48. GC65962 Dot1L-IN-5 Dot1L-IN-5 is a potent disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor with an IC50 SPA DOT1L of 0.17 nM. Dot1L-IN-5  Chemical Structure
  49. GC65927 PARP-2-IN-1 PARP-2-IN-1 is a potent and selective PARP-2 inhibitor with an IC50 of 11.5 nM. PARP-2-IN-1  Chemical Structure
  50. GC65918 AS-85 AS-85 is a potent ASH1L histone methyltransferase inhibitor (IC50=0.6 μM) with anti-leukemic activity. AS-85 strongly binds to the ASH1L SET domain, with the Kd value of 0.78μM. AS-85  Chemical Structure
  51. GC65907 KSQ-4279 KSQ-4279 (USP1-IN-1, Formula I) is a USP1 and PARP inhibitor (extracted from patent WO2021163530). KSQ-4279  Chemical Structure
  52. GC65899 AZ3391 AZ3391 is a potent inhibitor of PARP. AZ3391 is a quinoxaline derivative. PARP family of enzymes play an important role in a number of cellular processes, such as replication, recombination, chromatin remodeling, and DNA damage repair. AZ3391 has the potential for the research of diseases and conditions occurring in tissues in the central nervous system, such as the brain and spinal cord (extracted from patent WO2021260092A1, compound 23). AZ3391  Chemical Structure
  53. GC65879 Bomedemstat hydrochloride Bomedemstat (IMG-7289) hydrochloride is an orally active and irreversible lysine-specific demethylase 1 (LSD1) inhibitor. Bomedemstat hydrochloride can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat hydrochloride shows anti-cancer activities, inhibits cancer cell proliferation and induces apoptosis. Bomedemstat hydrochloride  Chemical Structure
  54. GC52188 MDL 800 MDL 800  Chemical Structure
  55. GC52166 NN-390 NN-390 is a potent and selective HDAC6 inhibitor, with an IC50 of 9.8 nM. NN-390 penetrates the blood-brain barrier (BBB). NN-390 shows study potential in metastatic Group 3 MB (medulloblastoma). NN-390  Chemical Structure
  56. GC65602 CFT8634 CFT8634 is a degrader targeting BRD9 extracted from patent WO2021178920A1 compound 174. CFT8634 can be used for the research of synovial sarcoma and SMARCB1-deleted solid tumors. CFT8634  Chemical Structure
  57. GC65581 MIND4-19 MIND4-19 is a potent SIRT2 inhibitor with an IC50 value of 7.0 μM. MIND4-19  Chemical Structure
  58. GC65574 SNIPER(BRD)-1 SNIPER(BRD)-1, consists of an IAP antagonist LCL-161 derivative and a BET inhibitor, (+)-JQ-1, connected by a linker. SNIPER(BRD)-1 induces the degradation of BRD4 via the ubiquitin-proteasome pathway. SNIPER(BRD)-1 also degrades cIAP1 , cIAP2 and XIAP with IC50s of 6.8 nM, 17 nM, and 49nM, respectively. SNIPER(BRD)-1  Chemical Structure
  59. GC65570 HIF1-IN-3 HIF1-IN-3 (compound F4) is a potent HIF1 inhibitor with an EC50 value of 0.9 μM. HIF1-IN-3 can be used for researching anticancer. HIF1-IN-3  Chemical Structure
  60. GC65569 BRD4 Inhibitor-24 BRD4 Inhibitor-24 (compound 3U) is a potent BRD4 inhibitor, BRD4 Inhibitor-24 shows antitumor activity against MCF7 and K652 cells, with IC50 values of 33.7 and 45.9 μM, respectively (extracted from patent CN107721975A). BRD4 Inhibitor-24  Chemical Structure
  61. GC65546 DNMT3A-IN-1 DNMT3A-IN-1 is a potent and selective DNMT3A inhibitor. DNMT3A-IN-1  Chemical Structure
  62. GC65509 PROTAC EZH2 Degrader-1 PROTAC EZH2 Degrader-1 (Compound 150d), a potent PROTAC EZH2 Degrader, exerts inhibitory effect on EZH2 methyltransferase activity with the IC50 of 2.7 nM. EZH2 plays an important role in many tumorigenesis and development processes. PROTAC EZH2 Degrader-1  Chemical Structure
  63. GC65506 BETd-246 BETd-246 is a second-generation and PROTAC-based BET bromodomain (BRD) inhibitor connected by ligands for Cereblon and BET, exhibiting superior selectivity, potency and antitumor activity. BETd-246  Chemical Structure
  64. GC65460 HDACs/mTOR Inhibitor 1 HDACs/mTOR Inhibitor 1 is a dual Histone Deacetylases (HDACs) and mammalian target of Rapamycin (mTOR) target inhibitor for treating hematologic malignancies, with IC50s of 0.19 nM, 1.8 nM, 1.2 nM and >500 nM for HDAC1, HDAC6, mTOR and PI3Kα, respectively. HDACs/mTOR Inhibitor 1 stimulates cell cycle arrest in G0/G1 phase and induce tumor cell apoptosis with low toxicity in vivo. HDACs/mTOR Inhibitor 1  Chemical Structure
  65. GC65456 T-448 T-448 is a specific, orally active and irreversible inhibitor of lysine-specific demethylase 1 (LSD1, an H3K4 demethylase), with an IC50 of 22 nM. T-448  Chemical Structure
  66. GC65453 JAK-IN-3 JAK-IN-3 (compound 22) is a potent JAK inhibitor, with IC50 values of 3 nM, 5 nM, 34 nM and 70 nM for JAK3, JAK1, TYK2 and JAK2, respectively. JAK-IN-3  Chemical Structure
  67. GC65426 CM-675 CM-675 is a dual phosphodiesterase 5 (PDE5) and class I histone deacetylases-selective inhibitor, with IC50 values of 114 nM and 673 nM for PDE5 and HDAC1, respectively. CM-675  Chemical Structure
  68. GC65405 JAK2-IN-6 JAK2-IN-6, a multiple-substituted aminothiazole derivative, is a potent and selective JAK2 inhibitor with an IC50 of 22.86 μg/mL. JAK2-IN-6 shows no activity against JAK1 and JAK3. JAK2-IN-6 has anti-proliferative effect against cancer cells. JAK2-IN-6  Chemical Structure
  69. GC65387 Tyk2-IN-5 Tyk2-IN-5 (compound 6) is a highly potent, selective and orally active Tyk2 inhibitor and targets the JH2 domain, with a Ki of 0.086 nM for Tyk2 JH2 and an IC50 of 25 nM for IFNα. Tyk2-IN-5  Chemical Structure
  70. GC65333 PT2399 PT2399 is a potent and selective HIF-2α antagonist, which directly binds to HIF-2α PAS B domain with an IC50 of 6 nM. PT2399 displays potent antitumor activity in vivo. PT2399  Chemical Structure
  71. GC65330 AES-135 AES-135, a hydroxamic acid-based pan-HDAC inhibitor, prolongs survival in an orthotopic mouse model of pancreatic cancer. AES-135 inhibits HDAC3, HDAC6, HDAC8, and HDAC11 with IC50s ranging from 190-1100 nM. AES-135  Chemical Structure
  72. GC65326 GNE-375 GNE-375 is a potent and highly selective BRD9 inhibitor with an IC50 of 5 nM. GNE-375 shows >100-fold selective for BRD9 over BRD4, TAF1, and CECR2. GNE-375 decreases BRD9 binding to chromatin. GNE-375  Chemical Structure
  73. GC65289 Lademirsen Lademirsen (SAR339375; RG-012) is a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of miR-21. Lademirsen  Chemical Structure
  74. GC65278 PIM1-IN-1 PIM1-IN-1 is a potent and highly selective PIM1/3 inhibitor, with IC50s of 7, 5530 and 70 nM for PIM1, PIM2, and PIM3, respectively, inhibits the phosphorylation of BAD, a downstream target of PIM, with an EC50 of 262 nM. PIM1-IN-1 shows no obvious effect on FLT3 or hERG binding. Antiproliferative and anti-cancer activity. PIM1-IN-1  Chemical Structure
  75. GC65269 ZXH-3-26 ZXH-3-26 is a PROTAC connected by ligands for Cereblon and BRD4 with a DC50/5h of 5 nM. The DC50/5h refers to half-maximal degradation after 5 hours of treatment of ~ 5 nM. ZXH-3-26  Chemical Structure
  76. GC65254 MC4355 MC4355 is a dual inhibitor of EZH2 and histone deacetylase (HDAC). MC4355  Chemical Structure
  77. GC65242 TFMB-(S)-2-HG TFMB-(S)-2-HG is a potent inhibitor of the 5'-methylcytosine hydroxylase TET2. TFMB-(S)-2-HG also inhibits the EglN prolyl hydroxylases. TFMB-(S)-2-HG has the potential for the research of acute myeloid leukemia (AML). TFMB-(S)-2-HG  Chemical Structure
  78. GC65206 FT895 FT895 is a potent and selective HDAC11 inhibitor with an IC50 of 3 nM. FT895  Chemical Structure
  79. GC65204 ZL0454 ZL0454 is a potent and selective Bromodomain-containing protein 4 (BRD4) inhibitor with an IC50 of 49 and 32 nM for BD1 and BD2. ZL0454  Chemical Structure
  80. GC65202 Nesuparib Nesuparib is a potent inhibitor of PARP. Nesuparib  Chemical Structure
  81. GC65201 Quercetagetin Quercetagetin (6-Hydroxyquercetin) is a flavonoid. Quercetagetin  Chemical Structure
  82. GC65186 DC-S239 DC-S239 is a selective histone methyltransferase SET7 inhibitor with an IC50 value of 4.59 μM. DC-S239 also displays selectivity for DNMT1, DOT1L, EZH2, NSD1, SETD8 and G9a. DC-S239 has anticancer activity. DC-S239  Chemical Structure
  83. GC65160 FHT-1015 FHT-1205 is a potent SMARCA4/SMARCA2 ATPase (BRG1 and BRM) inhibitor with IC50s of ≤10 nM (WO2020160180A1; compound 67). FHT-1015  Chemical Structure
  84. GC65147 PROTAC PARP1 degrader PROTAC PARP1 degrader is a PARP1 degrader based on MDM2 E3 ligand. It induces significant PARP1 cleavage and programmed cell death. PROTAC PARP1 degrader at 10 μM at 24 h inhibits MDA-MB-231 cell line with an IC50 of 6.12 μM. PROTAC PARP1 degrader  Chemical Structure
  85. GC65138 NCDM-32B NCDM-32B is a potent and selective KDM4 inhibitor that impaires viability and transforming phenotypes of breast cancer. NCDM-32B  Chemical Structure
  86. GC65135 VZ185 VZ185 is a potent, fast, and selective von Hippel-Lindau based dual degrader probe of BRD9 and BRD7 with DC50s of 4.5 and 1.8 nM, respectively. VZ185 is cytotoxic in EOL-1 and A-402 cells, with EC50s of 3 nM and 40 nM, respectively. VZ185  Chemical Structure
  87. GC65133 (S,R,S)-AHPC-C5-COOH (S,R,S)-AHPC-C5-COOH (VH032-C5-COOH) is a synthesized?E3 ligase ligand-linker conjugate, contains the VH032 VHL-based ligand and a linker to form PROTACs. VH-032 is a selective and potent inhibitor of VHL/HIF-1α interaction with a Kd of 185 nM, has the potential for the study of anemia and ischemic diseases. (S,R,S)-AHPC-C5-COOH  Chemical Structure
  88. GC65046 M1002 M1002 is a hypoxia-inducible factor-2 (HIF-2) agonist, and can enhance the expression of HIF-2 target genes. M1002 shows synergy with prolyl-hydroxylase domain (PHD) inhibitors. M1002  Chemical Structure
  89. GC65045 (S)-MRTX-1719 (S)-MRTX-1719 (example 16-7) is the S-enantiomer of MRTX-1719. (S)-MRTX-1719 is a PRMT5/MTA complex inhibitor, with an IC50 of 7070 nM. (S)-MRTX-1719  Chemical Structure
  90. GC65037 MM-589 TFA MM-589 TFA is a potent inhibitor of WD repeat domain 5 (WDR5) and mixed lineage leukemia (MLL) protein-protein interaction. MM-589 binds to WDR5 with an IC50 of 0.90 nM and inhibits the MLL H3K4 methyltransferase activity with an IC50 of 12.7 nM. MM-589 TFA  Chemical Structure
  91. GC65030 Sirtuin modulator 2 Sirtuin modulator 2 (Compound 132) is a sirtuin modulator with an ED50 equal or less than 50 μM. Sirtuin modulator 2  Chemical Structure
  92. GC65027 PRMT5-IN-20 PRMT5-IN-20 is a selective protein arginine methyltransferase 5 (PRMT5) inhibitor with anti-tumor activity. PRMT5-IN-20  Chemical Structure
  93. GC65019 SRT 1460 SRT 1460, a potent Sirtuin-1 (SIRT1) activator with an EC1.5 value of 2.9 μM, shows good selectivity for activation of SIRT1 versus SIRT2 and SIRT3 (EC1.5>300 μM), and is more potent than Resveratrol and the closest sirtuin homologues. SRT 1460  Chemical Structure
  94. GC64999 MS402 MS402 is a BD1-selective BET BrD inhibitor with Kis of 77 nM, 718 nM, 110 nM, 200 nM, 83 nM, and 240 nM for BRD4(BD1), BRD4(BD2), BRD3(BD1), BRD3(BD2), BRD2(BD1) and BRD2(BD2), respectively. MS402  Chemical Structure
  95. GC64968 SW-100 SW-100, a selective histone deacetylase 6 (HDAC6) inhibitor with an IC50 of 2.3 nM, shows at least 1000-fold selectivity for HDAC6 relative to all other HDAC isozymes. SW-100  Chemical Structure
  96. GC64960 BRD4 Inhibitor-10 BRD4 Inhibitor-10 is a potent BRD4-BD1 inhibitor extracted from patent WO2015022332A1, Compound II-25, has an IC50 of 8 nM. BRD4 Inhibitor-10  Chemical Structure
  97. GC64959 JAK/HDAC-IN-1 JAK/HDAC-IN-1 is a potent JAK2/HDAC dual inhibitor, exhibits antiproliferative and proapoptotic activities in several hematological cell lines. JAK/HDAC-IN-1 shows IC50s of 4 and 2 nM for JAK2 and HDAC, respectively. JAK/HDAC-IN-1  Chemical Structure
  98. GC64946 SRT 2183 SRT 2183 is a selective Sirtuin-1 (SIRT1) activator with an EC1.5 value of 0.36 μM. SRT 2183 induces growth arrest and apoptosis, concomitant with deacetylation of STAT3 and NF-κB, and reduction of c-Myc protein levels. SRT 2183  Chemical Structure
  99. GC64945 M1001 M1001 is a weak hypoxia-inducible factor-2α (HIF-2α) agonist. M1001 can bind to the HIF-2α PAS-B domain, with a Kd of 667 nM. M1001 can be used in chronic kidney disease research. M1001  Chemical Structure
  100. GC64942 CHDI-390576 CHDI-390576, a potent, cell permeable and CNS penetrant class IIa histone deacetylase (HDAC) inhibitor with IC50s of 54 nM, 60 nM, 31 nM, 50 nM for class IIa HDAC4, HDAC5, HDAC7, HDAC9, respectively, shows >500-fold selectivity over class I HDACs (1, 2, 3) and ~150-fold selectivity over HDAC8 and the class IIb HDAC6 isoform. CHDI-390576  Chemical Structure
  101. GC64941 PR5-LL-CM01 PR5-LL-CM01 is a potent protein arginine methyltransferase 5 (PRMT5) inhibitor (IC50= 7.5 μM). Anti-tumor activies. PR5-LL-CM01  Chemical Structure

Items 1 to 100 of 1258 total

per page
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Descending Direction